Trials / Conditions / Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation

27 registered clinical trials studyying Irritable Bowel Syndrome With Constipation — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Electro-acupuncture for Irritable Bowel Syndrome With Constipation NCT06219707	Nanyang Technological University	N/A
Recruiting	A Study of Virtual Reality and Linaclotide for IBS-C NCT05796388	Mayo Clinic	N/A
Enrolling By Invitation	Effect of Consuming a Nutraceutical Composition on Signs and Symptoms in Adult Patients With Irritable Bowel S NCT07103772	Universidad Autonoma de Nuevo Leon	N/A
Recruiting	Home Transcutaneous Electrical Acustimulation (TEA) NCT05519683	University of Michigan	Phase 2 / Phase 3
Unknown	Personalized Dietary Intervention Based on Microbiome Analysis vs FODMAP Diet for Irritable Bowel Syndrome NCT05646186	Istanbul Medipol University Hospital	N/A
Completed	A Multistrain Probiotic in Patients With Irritable Bowel Syndrome With Predominant Constipation NCT04997057	CEN Biotech	N/A
Completed	IBS-C Questionnaire Study NCT04968652	AstraZeneca	—
Completed	Safety and Efficacy of Non-alcoholic Beverage Based on Kombucha in Patients With Constipations NCT05164861	Vasily Isakov	N/A
Completed	Effect of Tai Chi as Treatment for IBS-C NCT04132804	Massachusetts General Hospital	N/A
Withdrawn	A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS NCT04214470	ProgenaBiome	—
Completed	Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C NCT04166058	AbbVie	Phase 3
Completed	Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome NCT04026113	AbbVie	Phase 3
Terminated	Efficacy and Safety of SYN-010 in IBS-C NCT03763175	Cedars-Sinai Medical Center	Phase 2
Completed	Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation NCT03596905	Bausch Health Americas, Inc.	Phase 2
Completed	Efficacy and Safety of a Food Supplement With Standardized Menthol, Limonene, and Gingerol Content in Patients NCT04484467	Federal Stare Budgetary Scientific Institution, Mental Health Research Center	N/A
Completed	An Evaluation of Cultured Milk Drink on Immune Status of Patients With Irritable Bowel Syndrome: Constipation NCT04647045	National University of Malaysia	N/A
Completed	The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation NCT03054506	Massachusetts General Hospital	N/A
Terminated	A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, W NCT02559817	Forest Laboratories	Phase 2
Completed	An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to A NCT02590432	Forest Laboratories	Phase 4
Completed	Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) NCT02559206	Ironwood Pharmaceuticals, Inc.	Phase 2
Completed	Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) NCT00938717	Ironwood Pharmaceuticals, Inc.	Phase 3
Completed	An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel NCT00765999	Forest Laboratories	Phase 3
Completed	An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel NCT00730171	Ironwood Pharmaceuticals, Inc.	Phase 3
Completed	Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irrit NCT00460811	Ironwood Pharmaceuticals, Inc.	Phase 2
Completed	A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c NCT00215566	Dynogen Pharmaceuticals	Phase 2
Completed	Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation NCT00380250	Sucampo Pharma Americas, LLC	Phase 3
No Longer Available	A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With C NCT00511771	Novartis	—